
BUD · NYSE
The supplied consensus is Buy from 11 analysts, with a mean price target of 97. The low and high targets are not available, so target clustering and the width of the spread cannot be measured. No named analyst-level targets, most-bullish analyst, least-bullish analyst, or rating and target revisions during the past week were supplied. The substantive debate in the available research is between AB InBev’s second-quarter earnings and revenue miss and the supporting indicators cited by the company and analysts: organic growth, premium brands, digital gains, stronger free cash flow, returning beer volumes and global share gains. Management’s reaffirmed 2026 view provides the bullish counterweight, but the evidence does not establish a direction for recent consensus revisions.